New research confirms that COVID-19 vaccines are safe and effective at reducing the cardiovascular complications that are a hallmark of COVID-19 infection.
Academic rigour, journalistic flair
Articles on Pfizer
Displaying 1 - 20 of 114 articles
mRNA vaccines are very safe, but this problem needed to be fixed for future mRNA therapies.
As the virus continues to mutate, COVID vaccines are updated. This brings us to the latest announcement about the new ‘monovalent’ vaccines.
The newly approved RSV vaccine could be rolled out by fall 2023, in time for the typical winter surge in RSV infections.
The CDC’s endorsement of the reformulated COVID-19 booster shots represents a major step in the effort to get more Americans boosted.
Early on, public health messaging focused on the need for vaccines to combat COVID-19. But far less attention has been given to the role of boosters in preventing deaths and reducing inequities.
We hear a lot about drug-resistant bacteria. The same thing can happen with viruses.
It’s natural to have questions about the risks and benefits of COVID vaccines in young children. Here’s what you need to know ahead of Australia’s rollout.
Is it time for a new generation of COVID vaccines? Here’s where the research is at.
On the horizon: A new omicron-focused version of the Moderna vaccine that may offer longer protection and a stronger immune response.
Waiving patent rights on COVID-19 vaccines and drugs is still crucial to ensure access globally, but the waiver on the table at the June World Trade Organization meeting doesn’t do the job.
Boosters and vaccinating children mean we’re relying on two pharmaceutical companies to supply Australia’s COVID vaccines. That needs to change.
The COVID-19 pandemic has brought immunology terms that are typically relegated to textbooks into our everyday vernacular. These stories helped us make sense of the ever-evolving science.
Fewer people reported needing to miss work after their booster, compared to their second dose.
Both companies say their drugs will work against the Omicron variant, though this is based on preliminary, lab-based research.
We’re reliant on overseas supply - and the many moving parts of delivery. Each of those parts require staff on the ground – and many workers in this system are likely being affected by Omicron.
Even with a variant like Omicron that may be more transmissible than earlier variants, vaccines remain the most effective tool for protection against COVID-19 and for ending the pandemic.
The Pfizer COVID-19 vaccine will be available for children aged 5-11 from January 10, after it cleared the final regulatory step. Here’s what you need to know.
The world needs to learn to live with the virus. And governments must follow the science and don’t distort it for political expediency.
Merck and Pfizer both have oral antiviral pills under review by the FDA. Such treatments could help turn the tide of the pandemic.
Top contributors
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor, The Children's Hospital at Westmead Clinical School, University of Sydney
-
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
-
Professor of Medicine, University of Virginia
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professorial Fellow, University of Canberra
-
Instructor of Human Immunology, Emory University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor, Infectious Diseases and Microbiology, The University of Queensland
-
Professor of Paediatrics and vaccinologist, Royal Childrens Hospital, University of Melbourne and Murdoch Childrens Research Institute (MCRI); Associate Dean International, University of Melbourne, Murdoch Children's Research Institute
-
Pharmacist and PhD Candidate, University of Sydney
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Professor and Director - Academic Excellence, Macquarie University
-
Professor of Business, University of Michigan
